Index RUT
P/E -
EPS (ttm) -4.53
Insider Own 1.10%
Shs Outstand 83.69M
Perf Week -22.56%
Market Cap 1.17B
Forward P/E -
EPS next Y -0.97
Insider Trans -21.48%
Shs Float 81.31M
Perf Month -30.09%
Income -357.80M
PEG -
EPS next Q -0.75
Inst Own 89.40%
Short Float / Ratio 17.60% / 8.29
Perf Quarter -51.35%
Sales 186.40M
P/S 6.30
EPS this Y -17.60%
Inst Trans 16.26%
Short Interest 14.31M
Perf Half Y -58.63%
Book/sh 0.32
P/B 40.66
EPS next Y 66.80%
ROA -58.70%
Target Price 39.27
Perf Year -49.57%
Cash/sh 3.54
P/C 3.68
EPS next 5Y 11.60%
ROE -903.30%
52W Range 11.10 - 37.98
Perf YTD -29.52%
Dividend -
P/FCF -
EPS past 5Y -4.10%
ROI -87.30%
52W High -65.75%
Beta 0.87
Dividend % -
Quick Ratio 4.70
Sales past 5Y 247.40%
Gross Margin 61.50%
52W Low 17.21%
ATR 1.20
Employees 534
Current Ratio 5.10
Sales Q/Q 104.60%
Oper. Margin -
RSI (14) 27.20
Volatility 10.27% 6.14%
Optionable Yes
Debt/Eq 14.77
EPS Q/Q 8.30%
Profit Margin -
Rel Volume 2.22
Prev Close 12.47
Shortable Yes
LT Debt/Eq 14.19
Earnings Aug 08 AMC
Payout -
Avg Volume 1.73M
Price 13.01
Recom 1.90
SMA20 -21.74%
SMA50 -32.75%
SMA200 -51.72%
Volume 3,823,236
Change 4.33%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-16-23 Upgrade
Exane BNP Paribas
Underperform → Neutral
$20
Oct-11-22 Initiated
Morgan Stanley
Equal-Weight
$27
Sep-22-22 Initiated
Goldman
Buy
$33
Oct-25-21 Downgrade
Wells Fargo
Overweight → Equal Weight
$35 → $17
Oct-15-20 Reiterated
Needham
Buy
$36 → $42
Aug-11-20 Resumed
Mizuho
Buy
$32
Mar-23-20 Downgrade
Goldman
Buy → Neutral
$32 → $15
Dec-02-19 Initiated
Goldman
Buy
Oct-30-19 Upgrade
Wells Fargo
Market Perform → Outperform
$20
Jun-11-19 Initiated
Barclays
Overweight
$28
Feb-15-19 Initiated
Wells Fargo
Market Perform
Feb-14-19 Initiated
H.C. Wainwright
Buy
$25
Jan-29-19 Initiated
Stifel
Buy
$50
Nov-16-18 Upgrade
Guggenheim
Neutral → Buy
Sep-17-18 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Apr-20-18 Reiterated
Mizuho
Buy
$54 → $48
Mar-27-18 Initiated
Needham
Buy
$42
Mar-05-18 Initiated
Goldman
Buy
$60
Jan-09-18 Downgrade
Guggenheim
Buy → Neutral
Dec-06-17 Reiterated
Mizuho
Buy
$37 → $54
Show Previous Ratings
Sep-19-23 04:18PM
(Investor's Business Daily) -17.31%
09:00AM
Sep-06-23 02:27PM
12:43PM
Aug-29-23 12:43AM
10:43AM
Loading…
Aug-22-23 10:43AM
08:00AM
Aug-21-23 04:09AM
Aug-14-23 04:03PM
(Investor's Business Daily)
08:00AM
Aug-08-23 06:15PM
04:05PM
Aug-03-23 09:19AM
Aug-01-23 08:00AM
Jul-29-23 11:39AM
03:00PM
Loading…
Jul-13-23 03:00PM
09:35AM
Jun-29-23 06:20AM
Jun-21-23 08:41PM
May-23-23 04:05PM
May-17-23 06:35AM
May-16-23 02:34AM
May-10-23 10:45AM
(Investor's Business Daily)
May-09-23 06:05PM
04:05PM
06:25AM
May-02-23 10:01AM
08:00AM
Apr-18-23 08:41AM
Apr-05-23 08:00AM
11:15PM
Loading…
Apr-04-23 11:15PM
Mar-30-23 08:00AM
Mar-29-23 05:36AM
Mar-07-23 08:00AM
Mar-03-23 08:11PM
Mar-01-23 10:33AM
(Thomson Reuters StreetEvents) -7.06%
Feb-28-23 07:45PM
04:06PM
04:05PM
Feb-27-23 08:00AM
06:21AM
Feb-24-23 05:10PM
(Investor's Business Daily)
07:48AM
Feb-23-23 08:00AM
Feb-22-23 10:00AM
Feb-21-23 04:05PM
Feb-20-23 10:00AM
Feb-03-23 02:15PM
(Investor's Business Daily)
Feb-02-23 12:00PM
Jan-30-23 10:20AM
Jan-27-23 12:47PM
(American City Business Journals)
Jan-23-23 04:14AM
Jan-09-23 08:00AM
Jan-06-23 06:00PM
Nov-22-22 08:00AM
Nov-17-22 08:00AM
Nov-10-22 05:32AM
(Simply Wall St.) +13.15%
Nov-09-22 08:00AM
Nov-08-22 06:05PM
04:05PM
Nov-04-22 08:00AM
Nov-02-22 10:01AM
Nov-01-22 01:01PM
10:01AM
08:00AM
Oct-24-22 12:02PM
Oct-20-22 08:00AM
Oct-17-22 08:00AM
Oct-10-22 08:00AM
Sep-21-22 08:00AM
Sep-19-22 08:00AM
Sep-17-22 08:36AM
Sep-15-22 04:06PM
04:05PM
Sep-12-22 09:32PM
04:01PM
Sep-09-22 03:10PM
02:39PM
02:30PM
Sep-08-22 05:13PM
(Yahoo Finance Video) +21.58%
10:36AM
07:44AM
07:27AM
07:00AM
07:00AM
(The Wall Street Journal)
Aug-11-22 11:10AM
(Investor's Business Daily)
Aug-10-22 04:35PM
Aug-09-22 06:15PM
04:05PM
Aug-02-22 04:05PM
Jul-27-22 08:00AM
Jul-20-22 05:26PM
Jul-17-22 10:46AM
Jun-15-22 08:19AM
May-23-22 08:00AM
May-17-22 06:46AM
May-10-22 05:45PM
04:05PM
May-05-22 06:45PM
May-03-22 08:00AM
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Moxie Dwight SVP, GC & Secretary Sep 06 Sale 17.06 11,000 187,704 44,066 Sep 07 05:37 PM Moxie Dwight SVP, GC & Secretary Sep 05 Sale 17.81 23,853 424,920 55,066 Sep 07 05:37 PM Foley Mark J CEO Aug 03 Sale 22.57 26,279 593,151 840,375 Aug 04 05:07 PM Foley Mark J CEO Jul 03 Sale 24.94 26,279 655,333 866,654 Jul 05 09:11 PM Schilke Tobin CFO Jul 03 Sale 25.04 1,701 42,593 79,896 Jul 05 09:11 PM Kolaja Carey OConnor Director Jun 15 Option Exercise 18.12 2,500 45,300 19,061 Jun 20 04:25 PM Kolaja Carey OConnor Director Jun 15 Sale 28.24 2,500 70,600 16,561 Jun 20 04:25 PM Foley Mark J CEO Jun 09 Sale 30.72 31,279 960,928 891,933 Jun 13 08:09 PM Sjuts Dustin S President Jun 09 Sale 30.82 5,000 154,096 147,347 Jun 13 08:09 PM Schilke Tobin CFO Jun 02 Sale 31.00 500 15,500 80,828 Jun 05 06:06 PM Schilke Tobin CFO Jun 01 Sale 30.57 2,701 82,570 81,328 Jun 05 06:06 PM Foley Mark J CEO May 15 Sale 34.55 70,447 2,433,725 923,212 May 16 08:29 PM Schilke Tobin CFO May 15 Sale 34.55 21,401 739,338 84,029 May 16 08:29 PM Moxie Dwight SVP, GC & Secretary May 15 Sale 34.55 21,401 739,338 69,165 May 16 08:29 PM Sjuts Dustin S President May 15 Sale 34.55 21,015 726,003 152,347 May 16 08:29 PM Schilke Tobin CFO May 01 Sale 31.70 3,201 101,472 63,081 May 02 04:01 PM Schilke Tobin CFO Apr 03 Sale 32.15 3,201 102,912 66,282 Apr 04 04:24 PM Foley Mark J CEO Mar 09 Sale 31.59 70,390 2,223,360 823,351 Mar 09 09:45 PM Sjuts Dustin S President Mar 09 Sale 31.59 21,508 679,358 123,934 Mar 09 09:45 PM Schilke Tobin CFO Mar 09 Sale 31.59 18,517 584,884 73,222 Mar 09 09:46 PM Moxie Dwight SVP, GC & Secretary Mar 09 Sale 31.59 18,496 584,220 55,547 Mar 09 09:46 PM Schilke Tobin CFO Mar 01 Sale 33.50 3,201 107,234 49,390 Mar 02 09:25 PM Schilke Tobin CFO Feb 01 Sale 34.60 3,201 110,755 54,676 Feb 02 09:38 PM Schilke Tobin CFO Jan 20 Sale 31.00 1,000 31,000 57,877 Jan 23 05:35 PM Schilke Tobin CFO Jan 09 Sale 27.16 3,701 100,525 58,877 Jan 10 08:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite